Alterations of Plasma Glutamine and Surgical Stress in Gastric Cancer Surgery

Tsutomu Hayashi1*, Hiroshi Yamamoto2, Takanobu Yamada3, Tsutomu Sato4, Toru Aoyama5, Yasushi Rino5, Munetaka Masuda5, Haruhiko Cho5, Akira Tsuburaya5, Takashi Ogata5, Takaki Yoshikawa5

Abstract

Background: The plasma glutamine levels are known to decrease after major surgery, which is related to a negative clinical outcome. However, the influence of surgical stress on the decrease in the plasma glutamine concentration is unclear. The aim of this study was to evaluate the change in glutamine in relation to the types of gastrectomy and approaches as well as the amount of surgical stress evaluated by serum interleukin-6 (IL-6) as an objective indicator.

Methods: This was a prospective observational study. The eligibility criteria were (1) gastric adenocarcinoma of the stomach confirmed by pathology and (2) patients scheduled to receive gastrectomy with lymphadenectomy for gastric cancer. Blood samples were taken at 7 AM on the day of surgery and at 12 h after surgery to measure the plasma glutamine and interleukin-6 (IL-6) levels.

Results: Between May 2011 and December 2011, 81 consecutive patients were enrolled in this study. The plasma glutamine level was significantly decreased in all patients, regardless of distal or total gastrectomy and laparoscopic or open surgery. No significant differences were observed in the IL-6 level between total and distal gastrectomy patients or between patients treated via a laparoscopic or open approach. Decreases in the plasma glutamine level were positively correlated with the logarithmically transformed-plasma IL-6 (logIL6) (r = 0.471, p < 0.001) overall.

Conclusions: Decreases in the glutamine concentration depended on the amount of surgical stress. When conducting a clinical trial to evaluate glutamine administration, personalized adjustment may be key to avoiding glutamine depletion in response to surgical stress.

Keywords: Gastric cancer; Surgical stress; Glutamine

Background

Complete tumor removal is essential for the cure of gastric cancer. Gastrectomy with D2 lymphadenectomy is accepted as a standard procedure worldwide [1]. Although D2 surgery is a safe procedure, morbidity and mortality are unavoidable. Surgical complications impair patients’ quality of life and prolong the hospital stay. Recently, infectious complications have been reported to be associated with a poor prognosis [2,3]. Peri-operative glutamine administration may be an attractive approach to reducing the rate of infectious complications, as plasma glutamine levels are decreased following various critical states and because low plasma glutamine levels are associated with a negative clinical outcome [4]. A shortage of glutamine may lead to dysfunction of the immune system, which can cause infectious complications related to invasion [5]. Based on these previous findings, several randomized controlled trials were conducted to evaluate the efficacy of peri-operative glutamine administration in critically ill patients. However, findings were conflicting, with some trials noting positive results [6-8] and others [9-11] negative results. These contradictory results may be explained by the hypothesis that the reduction or demand of glutamine depends on the severity of the surgical stress. Two previous studies [12,13] demonstrated that plasma glutamine concentrations were reduced following major surgery but not after minor surgery, suggesting that severity of the surgical stress determines the reduction of the plasma glutamine concentration.

Affiliation:
1 Department of Gastric Surgery, National Cancer Hospital, Tokyo, Japan
2 Research Institute for Bioscience Products & Fine Chemicals, Ajinomoto Co., Inc.
3 Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan
4 Department of Surgery, Yokohama City University, Yokohama, Japan
5 Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan

*Corresponding author:
Tsutomu Hayashi, Department of Gastric Surgery, National Cancer Hospital, Tokyo, Japan

Citation: Tsutomu Hayashi, Hiroshi Yamamoto, Takanobu Yamada, Tsutomu Sato, Toru Aoyama, Yasushi Rino, Munetaka Masuda, Haruhiko Cho, Akira Tsuburaya, Takashi Ogata, Takaki Yoshikawa. Alterations of Plasma Glutamine and Surgical Stress in Gastric Cancer Surgery. Journal of Surgery and Research 5 (2022): 462-467.

Received: July 14, 2022
Accepted: July 19, 2022
Published: July 29, 2022
concentration. However, the relationship between surgical stress and the reduction in the plasma glutamine remains unclear. Gastric cancer surgery may be a good candidate for such analyses, because surgical stress would be various depending on the approach or extent of gastrectomy. The present study therefore examined the change in the glutamine in relation to the type of gastrectomy and approach, as well as the amount of surgical stress evaluated by serum interleukin-6 (IL-6) as an objective indicator.

Methods

Patients

This was a prospective observational study. The eligibility criteria were (1) gastric adenocarcinoma of the stomach confirmed by pathology and (2) patients scheduled to receive gastrectomy with D1 or D2 lymphadenectomy for gastric cancer. The extent of lymph node dissection was determined by the JGCA guidelines [1]. Distal gastrectomy was selected when the tumors were located at the lower to middle third of the stomach, while total gastrectomy was chosen when the tumors were located at the upper third of the stomach. Laparoscopic distal gastrectomy was only performed when eligible patients with clinical stage I were enrolled in the phase III trial comparing open and laparoscopic surgery and had been randomly allocated to the laparoscopic approach. Laparoscopic total gastrectomy was only selected when eligible patients with clinical T1 disease were enrolled in the in-house phase II trial to evaluate feasibility. All other patients received open surgery. All clinical information was obtained prospectively.

Study schedule and measurements

The patients were admitted to the hospital by two days before surgery and allowed to eat until midnight the day before surgery. On the day of surgery, patients were allowed to drink Oral Rehydration Solution (OS-1°) until 3 h before surgery but did not receive any preoperative intravenous infusion. Blood samples were taken at 7 AM on the day of surgery and at 12 h after surgery to measure the IL-6 and glutamine levels. Glutamine concentrations were measured by high-performance liquid chromatography (HPLC)–electrospray ionization (ESI)–mass spectrometry (MS) by precolumn derivatization. These analytical methods have been described elsewhere [14]. Plasma IL-6 levels were measured using a chemiluminescent enzyme immunoassay (CLEIA).

Statistical analyses

The SPSS software program, version 19.0 (Statistical Package for Social Sciences, Chicago, IL, USA), was used for statistical calculations. To compare the IL-6 levels between surgical procedures, the Mann–Whitney U test was used. The differences in the plasma glutamine concentration before and 12 h after surgery were examined using a paired t-test. Differences were considered significant at p<0.05 in both analyses. The change in the plasma concentration of glutamine was calculated by subtracting the value at 12 h after surgery from the preoperative value. The values of IL-6 were converted to log scale (log10) referring previous studies [15-18]. This prospective observational study was approved by the research ethics committee of Kanagawa Cancer Center, Yokohama.

Results

Between May and December 2011, 81 consecutive patients were prospectively enrolled in this study. No patient refused to enter the study during this period.

Clinicopathological characteristics

The clinicopathological characteristics are shown in table 1. Fourteen patients (17%) received pre-operative chemotherapy. Laparoscopic surgery was performed in 17 patients (21%), laparoscopy-assisted total gastrectomy (LATG) in 4 and laparoscopy-assisted distal gastrectomy (LADG) in 13. Forty-four patients underwent D2 lymphadenectomy, whereas 37 underwent D1. All patients who underwent total gastrectomy with D2 lymphadenectomy received splenectomy. The median intraoperative blood loss was 270 ml (range: 5-2045 ml), and 4 patients received blood transfusion during the operation.

The clinicopathological characteristics are compared between the open and laparoscopic approaches in table 2. The patients who received pre-operative chemotherapy underwent open gastrectomy. In addition, 9 patients (53%) had an ASA score 1 in laparoscopic surgery, while 16 (25%) had ASA 1 in open surgery. There were significant differences in the surgical details and disease stage between the open and laparoscopic surgery patients.

Plasma concentration of glutamine

The plasma concentrations of glutamine before and at 12 h after surgery are shown in table 3. The plasma glutamine level was significantly decreased in all patients after surgery, regardless of distal or total gastrectomy or laparoscopic or open surgery (table 2, p<0.001 by the paired t-test). The decreases in the plasma concentrations of glutamine before and at 12 h after surgery are shown in figure 1. There were no significant differences between the total gastrectomy and distal gastrectomy patients (p=0.117) or between the patients treated with the laparoscopic and open approach (p=0.927).

Plasma levels of IL-6

The median plasma level of IL-6 at 12 h after surgery was 55 pg/dl (range: 10-858 pg/dl) overall, 68.0 pg/dl (range: 10-858 pg/dl) in the total gastrectomy patients, 53.0 pg/dl (range: 14-405 pg/dl) in the distal gastrectomy patients, 58 pg/dl (range: 24-217 pg/dl) in the laparoscopic surgery patients and 55 pg/dl (range: 10-858 pg/dl) in the laparotomy patients. There were no significant differences between the total gastrectomy and distal gastrectomy groups (p=0.398 by Mann–Whitney U test) or between the laparoscopic and open approach groups (p=0.894 by Mann–Whitney U test).

Analyses of the correlations between decreases in plasma glutamine and IL-6

Overall, a decrease in the plasma glutamine level was...
positively correlated with the logarithmically transformed-plasma IL-6 (log IL6); r=0.471 p<0.001 in overall, r=0.500 p<0.001 in open approach, and r=0.241 p=0.351 in laparoscopic approach (Figure 2a). When stratified by each procedure, strong correlations between the log IL-6 and a decrease in the plasma glutamine levels were observed in both the open and laparoscopic total gastrectomy patients; r=0.677 p<0.001 in overall, r=0.677 p<0.001 in open approach, and r=0.775 p=0.2251 in laparoscopic approach (Figure 2b). In contrast, a significant but weak correlation was found only in the overall patients who received distal gastrectomy; r=0.286 p=0.046 in overall. No significant correlation was observed when stratified by open and laparoscopic surgery; r=0.313 p=0.063 in open approach, and r=0.098 p=0.751 in laparoscopic approach (Figure 2b).

**Discussion**

This is the first study to examine the correlation between decreases in the plasma glutamine levels and the amount of surgical stress. As previously reported [12,13,19], the plasma glutamine concentration was decreased after gastrectomy, which is a major abdominal surgery, regardless of total or distal gastrectomy and laparoscopic or open surgery. Furthermore, the present study

| Table 1: Clinicopathologic characteristics. |
|---------------------------------------------|
|                                           |
| Overall N=81                               |
| Total gastrectomy N=32                     |
| Distal gastrectomy N=49                    |
| **Age**                                    |
| Median (range)                             |
| Overall                                   |
| 67 (36-84)                                 |
| Total gastrectomy                         |
| 68 (45-84)                                 |
| Distal gastrectomy                        |
| 65 (36-83)                                 |
| **Gender**                                 |
| Male/Female                                |
| Overall                                   |
| 55/26                                     |
| Total gastrectomy                         |
| 25/7                                      |
| Distal gastrectomy                        |
| 30/19                                     |
| **ASA score**                              |
| Overall                                   |
| 1/2/3                                     |
| Total gastrectomy                         |
| 25/55/1                                   |
| Distal gastrectomy                        |
| 10/22/0                                   |
| **Pre-operative chemotherapy**             |
| No/Yes                                    |
| Overall                                   |
| 14/67                                     |
| Total gastrectomy                         |
| 22/10                                     |
| Distal gastrectomy                        |
| 45/4                                      |
| **Albumin (g/dl)**                         |
| Mean (SD)                                  |
| Overall                                   |
| 4.43 (0.42)                               |
| Total gastrectomy                         |
| 4.49 (0.62)                               |
| Distal gastrectomy                        |
| 4.20 (0.48)                               |
| **Hemoglobin (g/dl)**                     |
| Mean (SD)                                  |
| Overall                                   |
| 12.9 (1.9)                                |
| Total gastrectomy                         |
| 12.7 (2.1)                                |
| Distal gastrectomy                        |
| 13 (1.8)                                  |
| **Tumor location**                        |
| U/M/L                                     |
| Overall                                   |
| 23/26/32                                  |
| Total gastrectomy                         |
| 23-06-2003                                |
| Distal gastrectomy                        |
| 0/20/29                                   |
| **Tumor depth**                           |
| T1/T2/T3/T4                               |
| Overall                                   |
| 39/10/13/19                              |
| Total gastrectomy                         |
| 9/4/9/10                                  |
| Distal gastrectomy                        |
| 30/6/4/9                                  |
| **Nodal involvement**                     |
| No/N1/N2/N3                               |
| Overall                                   |
| 49/12/7/13                               |
| Total gastrectomy                         |
| 15/5/2/10                                |
| Distal gastrectomy                        |
| 34/7/5/3                                  |
| **Stage (TNM 7th)**                       |
| I/II/III/IV                               |
| Overall                                   |
| 46/14/18/3                               |
| Total gastrectomy                         |
| 13/5/11/3                                |
| Distal gastrectomy                        |
| 33/9/7/0                                  |
| **Surgical procedure**                    |
| Laparotomy/Laparoscopic surgery           |
| Overall                                   |
| 64/17                                    |
| Total gastrectomy                         |
| 28/4                                     |
| Distal gastrectomy                        |
| 36/13                                    |
| **Extent of lymphadenectomy**             |
| D1/D2                                     |
| Overall                                   |
| 37/44                                    |
| Total gastrectomy                         |
| 13/19                                    |
| Distal gastrectomy                        |
| 24/25                                    |
| **Splenectomy**                           |
| No/Yes                                    |
| Overall                                   |
| 62/19                                    |
| Total gastrectomy                         |
| 13/19                                    |
| Distal gastrectomy                        |
| 49/0                                     |
| **Pancreatectomy**                        |
| No/Yes                                    |
| Overall                                   |
| 78/3                                     |
| Total gastrectomy                         |
| 29/3                                     |
| Distal gastrectomy                        |
| 49/0                                     |
| **Intraoperative blood loss (ml)**        |
| Median (range)                            |
| Overall                                   |
| 270 (5-2045)                             |
| Total gastrectomy                         |
| 380 (30-2045)                            |
| Distal gastrectomy                        |
| 190 (5-1660)                             |
| **Blood transfusion**                     |
| No/Yes                                    |
| Overall                                   |
| 4/77                                     |
| Total gastrectomy                         |
| 30/2                                     |
| Distal gastrectomy                        |
| 47/2                                     |

*: The American Society of Anesthesiologists score
**: U: upper third; M, Middle third; L, Lower third
***: Tumor depth and nodal involvement were based on the TNM 7th edition.
clearly demonstrated that decreases in the plasma glutamine level were positively correlated with the surgical stress estimated by logarithmically transformed plasma IL-6. We therefore confirmed our hypothesis of this study. When conducting clinical trials to evaluate glutamine administration, personalized adjustment may be key to avoiding glutamine depletion in response to surgical stress. Interestingly, the plasma IL-6 values were similar between the open and laparoscopic surgery groups. Furthermore, a reduction in the plasma glutamine was similarly found, regardless of open or laparoscopic surgery. Laparoscopic surgery has been considered less invasive than an open approach. In the present study, patients who received laparoscopic surgery had a higher proportion of early-stage disease, less-extensive nodal dissection, no splenectomy, and less blood loss than those in the open surgery group. The surgical invasiveness may therefore have been greater in the open surgery group than in those treated via a laparoscopic approach. The extent of lymphadenectomy, rate of splenectomy, and intraoperative blood loss were significantly different between the two approaches. Similarly, with regard to surgical factors, the extent of lymphadenectomy, rate of splenectomy, and intraoperative blood loss were significantly different. These findings may suggest that homogeneity of the patients and surgery was higher in laparoscopic surgery than in open surgery, resulting

study targeting only clinical stage I demonstrated that increase of IL-6 was not different between open surgery and laparoscopic approach [21]. This disagreement had been also reported in colorectal surgery [21-23]. Thus, it remains controversial whether the laparoscopic approach has less surgical stress as compared with open surgery. Resection of the stomach itself might be a major determinant of surgical stress in gastric cancer surgery than difference of open or laparoscopic approach. This idea can also be applied in cases of total or distal gastrectomy. Decreases in the plasma glutamine levels were positively correlated with surgical stress estimated by logarithmically transformed plasma IL-6. When stratified by approach, this correlation was weakened, especially in the laparoscopic approach. As a result, there were no significant correlations in laparoscopic total and distal gastrectomy. These results may be explained by less variation in the IL-6 values in laparoscopic surgery than in the open approach. Looking at the patients’ background factors, the ASA scores, preoperative chemotherapy, and stage were significantly different between the two approaches. Similarly, with regard to surgical factors, the extent of lymphadenectomy, rate of splenectomy, and intraoperative blood loss were significantly different. These findings may suggest that homogeneity of the patients and surgery was higher in laparoscopic surgery than in open surgery, resulting

Figure 1: Decreases in the plasma glutamine levels before and at 12 h after surgery compared between procedure (a) and approach (b).

Figure 2: Logarithmically transformed-plasma IL-6 and decreases in the plasma glutamine levels (a) in all patients and (b) stratified by procedure.
in narrowed variations in surgical stress and decreases in plasma glutamine in laparoscopic surgery. The present study has several limitations. At first, the study only showed just an association of glutamine and IL-6, which did not mean direct causal relationship. Second, IL-6 level was only measured 12 hours after surgery. This might not represent the highest IL-6 caused by surgery. Finally, the sample size may be not enough to strictly interpret variation in the IL-6 value effected by various factors involved in surgical stress including surgical factors and patient’s backgrounds.

Conclusions

In conclusion, the plasma glutamine concentration was decreased after gastrectomy, regardless of the approach and type of gastrectomy. Decreased glutamine concentrations depended on the amount of surgical stress. This may account for the contradictory results of phase III trials of glutamine administration. Thus, personalized adjustment may be necessary when conducting clinical trials to evaluate glutamine administration.

Abbreviations

IL-6: interleukin-6

Highlights

Plasma glutamine was decreased depending on the amount of surgical stress.

Declarations

Funding

This work being reported was partially funded by Ajinomoto Co., Ltd. All authors declare no commercial associations that might represent conflicts of interest with this article and have nothing to disclose.

Ethics approval and consent to participate

This study was conducted in accordance with the Declaration of Helsinki. This study was approved by the Ethics Committee of

Table 2: Comparison between open and laparoscopic approach

|                          | Open N=64 | Lap N=17 | P value |
|--------------------------|-----------|----------|---------|
| Age                      |           |          |         |
| Median (range)           | 62.0 (38-79) | 67.5 (36-84) | 0.234   |
| Gender                   |           |          |         |
| Male/Female              | 45/19    | 10/7    | 0.392   |
| ASA score*               |          |          |         |
| 1/2/3                    | 16/48/0  | 09-07-2001 | 0.008   |
| Pre-operative chemotherapy|         |          |         |
| No/Yes                   | 50/14    | 17/0    | 0.034   |
| Albumin (g/dl)           |          |          |         |
| Mean (SD)                | 4.40 (0.47) | 4.40 (0.21) | 0.772   |
| Hemoglobin (g/dl)        |          |          |         |
| Mean (SD)                | 12.9 (1.99) | 12.7 (1.65) | 0.807   |
| Tumor location**         |          |          |         |
| U/M/L                    | 20/20/24 | 03-06-2008 | 0.564   |
| Stage (TNM 7th)          |          |          |         |
| I/II/III/IV              | 30/13/18/3 | 16/1/0/0 | 0.004   |
| Extent of lymphadenectomy|          |          |         |
| D1/D2                    | 24/40    | 13/4    | 0.006   |
| Splenectomy              |          |          |         |
| No/Yes                   | 45/19    | 17/0    | 0.009   |
| Pancreanectomy           |          |          |         |
| No/Yes                   | 3/61     | 0/17    | 1.000   |
| Intraoperative blood loss (ml) | |     |         |
| Median (range)           | 340 (50-2045) | 45 (5-270) | <0.001  |
| Blood transfusion        |          |          |         |
| No/Yes                   | 45/4     | 0/17    | 0.574   |

*: The American Society of Anesthesiologists score
**: U, upper third; M, Middle third; L, Lower third

Citation: Tsutomu Hayashi, Hiroshi Yamamoto, Takanobu Yamada, Tsutomu Sato, Toru Aoyama, Yasushi Rino, Munetaka Masuda, Haruhiko Cho, Akira Tsuburaya, Takashi Ogata, Takaki Yoshikawa. Alterations of Plasma Glutamine and Surgical Stress in Gastric Cancer Surgery. Journal of Surgery and Research 5 (2022): 462-467.
References

1. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 20 (2017): 1-19.

2. Tokunaga M, Taniwasa Y, Bando E, et al. Poor survival rate in patients with postoperative intra-abdominal infectious complications following curative gastrectomy for gastric cancer. Ann Surg Oncol 20 (2013): 1575-1583.

3. Hayashi T, Yoshikawa T, Aoyama T, et al. Impact of infectious complications on gastric cancer recurrence. Gastric Cancer 18 (2015): 368-374.

4. Oudemans-van Straaten HM, Bosman RJ, Treskes M, et al. Plasma glutamine depletion and patient outcome in acute ICU admissions. Intensive Care Med 27 (2001): 84-90.

5. Parry-Billings M, Evans J, Calder PC, et al. Does glutamine contribute to immunosuppression after major burns? Lancet 336 (1990): 523-525.

6. Jacobi CA, Ordemann J, Zuckermann H, et al. The influence of alanyl-glutamine on immunologic functions and morbidity in postoperative total parenteral nutrition. Preliminary results of a prospective randomized trial. Zentralbl Chir 124 (1999): 199-205.

7. Klek S, Kulig J, Szczepanik AM, et al. The clinical value of parenteral immunonutrition in surgical patients. Acta Chir Belg 105 (2005): 175-179.

8. Oguz M, Kerem M, Bedirti A, et al. L-alanin-L-glutamine supplementation improves the outcome after colorectal surgery for cancer. Colorectal Dis 9 (2007): 1238-1244.

9. Jo S, Choi SH, Heo JS, et al. Missing effect of glutamine supplementation on the surgical outcome after pancreaticoduodenectomy for periampullary tumors: a prospective, randomized, double-blind, controlled clinical trial. World J Surg 30 (2006): 1974-1982.

10. Gianotti L, Braga M, Biffi R, et al. Perioperative intravenous glutamine supplementation in major abdominal surgery for cancer: a randomized multicenter trial. Ann Surg 250 (2009): 684-690.

11. Heyland D, Muscedere J, Wischmeyer PE, et al. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med 368 (2013): 1489-1497.

12. Parry-Billings M, Baigrie RJ, Lamont PM, et al. Effects of major and minor surgery on plasma glutamine and cytokine levels. Arch Surg 127 (1992): 1237-1240.

13. Viggiani E, Passavanti MB, Pace MC, et al. Plasma glutamine decreases immediately after surgery and is related to incisiveness. J Cell Physiol 227 (2012): 1988-1991.

14. Yoshida H, Kondo K, Yamamoto H, et al. Validation of an analytical method for human plasma free amino acids by high-performance liquid chromatography ionization mass spectrometry using automated precolumn derivatization. J Chromatogr B Analyt Technol Biomed Life Sci 12 (2015): 993-996.

15. Sanders J, Hawe E, Brull DJ, et al. Higher IL-6 levels but not IL6 -174G>C or -572G>C genotype are associated with post-operative complication following coronary artery bypass graft (CABG) surgery. Atherosclerosis 204 (2009): 196-201.

16. Miwa K, Tanaka M, Okazaki S, et al. Association between interleukin-6 levels and first-ever cerebrovascular events in patients with vascular risk factors. Arterioscler Thromb Vasc Biol 33 (2013): 400-405.

17. Shah T, Zabaneh D, Gaunt T, et al. Gene-centric analysis identifies variants associated with interleukin-6 levels and shared pathways with other inflammation markers. Circ Cardiovasc Genet 6 (2013): 163-170.

18. Park SY, Kim J, Kim OJ, et al. Predictive value of circulating interleukin-6 and heart-type fatty acid binding protein for three months clinical outcome in acute cerebral infarction: multiple blood markers profiling study. Crit Care 17 (2013): R45.

19. Blomqvist BI, Hammarqvist F, Von der Decken A, et al. Glutamine and alpha-ketoglutarate prevent the decrease in muscle free glutamine concentration and influence protein synthesis after total hip replacement. Metabolism 44 (1995): 1215-1222.

20. Hayashi H, Ochiai T, Shimada H, et al. Prospective randomized study of open versus laparoscopy-assisted distal gastrectomy with extraperigastric lymph node dissection for early gastric cancer. Surg Endosc 19 (2005): 1172-1176.

21. Aoyama T, Yoshikawa T, Hayashi T, et al. Randomized comparison of surgical stress and the nutritional status between laparoscopy-assisted and open distal gastrectomy for gastric cancer. Ann Surg Oncol 21 (2014): 1983-1990.

22. Leung KL, Lai PB, Ho RL, et al. Systemic cytokine response after laparoscopic-assisted resection of rectosigmoid carcinoma: A prospective randomized trial. Ann Surg 231 (2000): 506-511.

23. Tang CL, Ou KW, Tai BC, et al. Randomized clinical trial of the effect of open versus laparoscopically assisted colectomy on systemic immunity in patients with colorectal cancer. Br J Surg 88 (2001): 801-807.

24. Dunker MS, Ten Hove T, Bemelman WA, et al. Interleukin-6, C-reactive protein, and expression of human leukocyte antigen-DR on peripheral blood mononuclear cells in patients after laparoscopic vs. conventional bowel resection: a randomized study. Dis Colon Rectum 46 (2003): 1238-1244.